|
Compounds as TDP-43 LLPS Modulators
This technology provides compounds and pharmaceutical compositions comprising small molecules that inhibit the formation of TAR DNA-binding protein 43 (TDP-43) condensates, which are protein aggregates linked to various neurodegenerative diseases including Alzheimer’s disease. By suppressing the formation of these aggregates, these molecules improve...
Published: 2/19/2024
|
Inventor(s): Xinglong Wang
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences
|
|
Broad Applications of PROTACS for Targeted Protein Degradation Employing a Molecular Glue-Linker-Warhead Approach
This technology is a high-affinity E3-ligase binder, which has been optimized toward the specific proteolysis targeting chimera (PROTAC) mediated degradation of particular proteins. A PROTAC is a heterobifunctional molecule composed of two active domains and a linker, capable of removing specific unwanted proteins. This technology opens the door for...
Published: 2/6/2024
|
Inventor(s): Christopher Hulme, Kevin Schofield
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Bioorthogonal Activation of PROTAC Prodrugs
Utilizing proteolysis targeting chimeras (PROTACs) to degrade proteins that are important for tumorigenesis has become a potential therapeutic strategy for cancer. This innovation is an on-demand prodrug strategy called click-release proteolysis targeting chimeras, or “crPROTACs.” The crPROTACs strategy utilizes bioorthogonal chemistry and...
Published: 1/16/2024
|
Inventor(s): Wei Wang, Mengyang Chang, Giri Gnawali
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Oncology, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Small Molecules
|
|
Discovery of Novel DYRK1A Inhibitors
DYRK1A has been implicated in multiple disease states, including Alzheimer's Disease and Down Syndrome. Researchers have discovered a new chemotype that has been exemplified with significant DYRK1A activity and have developed brain-penetrant small molecule DYRK1A inhibitors toward Alzheimer's and the cognitive deficits of Down Syndrome. Future...
Published: 1/10/2024
|
Inventor(s): Christopher Hulme, Timothy Chavez, Nathan Bedard
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Small Molecules
|
|
HCV3 for Multiple Indications involving Alpha2B Receptor Modulation
The invention is a preclinical drug candidate (HCV3) based on the discovery that substituted 1-arylalkyl-4-acylaminopiperide compounds have shown to be effective antagonists of mu-, delta-, and kappa-opioid receptors and/or alpha-2-adrenoreceptors. HCV3 can be used to treat clinical conditions that are due to activation of any one or more of the receptors,...
Published: 3/12/2024
|
Inventor(s): Victor Hruby, Ruben Vardanyan
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Redox-Activated Pro-Chelators
Novel molecular design extends the reach of iron chelators to applications in cancer chemotherapy. This invention not only recognizes the higher demand of iron that characterizes cancer cells, but also takes into account other physiological differences between malignant cells and the surrounding tissue. Specifically, pro-drugs are designed to activate...
Published: 3/12/2024
|
Inventor(s): Elisa Tomat, Eman Akam, Yu-Shien Sung
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Blood & Lymphatic Disease, Technology Classifications > Healthcare Portfolios > Oncology
|
|
Bioinspired Glycolipids as Fugitive Dust Suppression Agents
This technology involves the utilization of bioinspired glycolipids to reduce fugitive dust emissions.
Background:
Fugitive dust is defined by the EPA as dust that "arises from the mechanical disturbance of granular material exposed to air" and common sources of such materials include constructions sites, dirt roads, barren fields, mining...
Published: 8/23/2023
|
Inventor(s): Minkyu Kim, David Hogan, Raina Maier
Keywords(s):
Category(s): Technology Classifications > Energy, Cleantech & Environmental, Technology Classifications > Energy, Cleantech & Environmental > Remediation > Soil, Technology Classifications > Life Sciences > Small Molecules
|
|
DYRK/CLK PROTACS
This invention describes a set of novel molecules that target and degrade DYRK/CLK for several potential therapeutic purposes.
Background:
Proteolysis-targeting chimeric molecules (PROTACs) are small molecules used to decrease a gene’s protein expression by targeting the protein for ubiquitination and degradation after it is created. This mechanism...
Published: 11/16/2023
|
Inventor(s): Christopher Hulme, Kevin Schofield, Walter Becker, Garrit Wilms
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Small Molecule Chaperones of CLN1 and CLN2
The inventors here have identified a method of treating Batten Disease with small molecules that target palmitoyl-protein thioesterase 1 (PPT1), tripeptidyl peptidase 1 (TPP1), enzymes that are deficient and less active in Batten disease or Neuronal Ceroid Lipofuscinosis. The CLN1 and CLN2 genes regulate the production of these enzymes, respectively.
Background:
Batten...
Published: 7/12/2023
|
Inventor(s): May Khanna, Lipsa Jena
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Iron-targeting to stop cancer growth in malignant cells
This invention comprises a class of tetrazolium-based prochelators for targeting and binding intracellular iron for selective cancer cell antiproliferation or other iron dysregulation. Various analogues within this class of chemistry can be tuned to the redox potential for selective targeting of cancer cell types. Following cellular uptake, the tetrazolium...
Published: 3/12/2024
|
Inventor(s): Elisa Tomat, Zoufeng Xu
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Oncology, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications, Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences
|
